Staphylococcus aureus bacteriophage SapLY01 and application thereof
By developing the Staphylococcus aureus phage SapLY01, the problems of narrow phage host profile and poor stability in the prior art were solved, effective inhibition and treatment of Staphylococcus aureus were achieved, and new food safety and disease treatment options were provided.
Patent Information
- Application Number
- CN202411153752.1
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2024-08-21
- Publication Date
- 2024-12-03
AI Technical Summary
In the prior art, the phage of Staphylococcus aureus has problems with narrow host profile and poor temperature and pH stability, which leads to poor effectiveness in inhibiting Staphylococcus aureus, and the problem of drug-resistant bacteria caused by antibiotic treatment is difficult to solve.
A Staphylococcus aureus phage SapLY01 has developed a broad cleavage spectrum, good temperature and pH stability, which can effectively inhibit or kill bacteria that cannot be affected by antibiotics, and improve their titers through isolation, genome sequencing and optimization preparation processes. stability.
SapLY01 phage has a short incubation period, small toxic side effects, high safety, can quickly kill Staphylococcus aureus, effectively inhibit environmental pollution and treat infections, is suitable for disinfection of food and aquatic products, and has a wide range of temperature and pH adaptability.
Smart Images

Figure CN119060963A_ABST
Abstract
Description
Technical Field
[0001] The invention relates to the field of biotechnology, and in particular to a Staphylococcus aureus phage SapLY01 and an application thereof. Background Art
[0002] Staphylococcus aureus is a representative bacterium of the genus Staphylococcus. It is highly pathogenic and can cause mild skin infections to serious life-threatening diseases in humans and livestock. It can not only cause local suppurative infections, such as furuncle, carbuncle, folliculitis and surgical incisions, but also cause systemic infections, such as pneumonia, osteomyelitis, meningitis, suppurative arthritis, endocarditis, bacteremia and sepsis. Staphylococcus aureus has low nutritional requirements and strong resistance to the outside world, so it can be widely present in nature and is distributed in air, soil, various water bodies and livestock-related environments. It is reported that food poisoning incidents caused by Staphylococcus aureus account for about 33% of bacterial poisoning incidents worldwide, and bacterial food poisoning incidents in my country rank fourth each year. Among the pollution sources, food is seriously contaminated by Staphylococcus aureus, among which milk and dairy products, fresh meat and quick-frozen food are most susceptible to contamination. It can be seen that inhibiting the contamination of Staphylococcus aureus is an urgent need for global food safety.
[0003] In the prevention and treatment of Staphylococcus aureus, traditional antibiotic treatments are widely used in overdoses and abused beyond the scope, and are not used according to strict standards, resulting in the continuous emergence and spread of drug-resistant and multidrug-resistant Staphylococcus aureus. Antibiotic treatments are gradually losing their effectiveness, and there is an urgent need to develop and research new, effective antibacterial preparations that are not affected by drug resistance.
[0004] Bacteriophages are viruses that use bacteria, fungi, actinomycetes, spirochetes and other microorganisms as hosts. They can cause host bacteria to lyse and are specific, self-increase rapidly, and are highly safe. They are widely present in the environment. Phage preparations have the characteristics of strong specificity, high efficiency, and easy mass preparation. In recent years, they have been considered as a favorable weapon to restrain drug-resistant bacteria. The United States, Europe and other countries have approved certain phage preparations for disease treatment and food sterilization and have achieved remarkable results. For example, Professor Ryland Young used three strains of phages to cure patients infected with "super bacteria" - multidrug-resistant Acinetobacter baumannii, and Professor Dedrick RM used phages to successfully cure patients infected with drug-resistant Mycobacterium tuberculosis after bilateral lung transplantation.
[0005] Some Staphylococcus aureus phages have been disclosed in the prior art, but many of these phages have limitations such as narrow host spectrum and poor temperature and pH stability. Summary of the invention
[0006] In view of the above technical problems, the present invention provides a Staphylococcus aureus phage SapLY01, which has a wide lysis spectrum and can inhibit or kill bacteria that antibiotics cannot act on, aiming to provide a new treatment plan for Staphylococcus aureus infection and a new disinfection method for environmental pollution and various diseases caused by Staphylococcus aureus.
[0007] To achieve the above purpose, the technical solution provided by the present invention is as follows:
[0008] A Staphylococcus aureus phage SapLY01, wherein the Staphylococcus aureus phage SapLY01 is Staphylococcus aureus phage SapLY01, which was deposited in China Center for Type Culture Collection on January 4, 2024, with a deposit number of CCTCC NO: M 2024014, and a deposit address: China Center for Type Culture Collection of Wuhan University, Bayi Road, Wuchang District, Wuhan City, Hubei Province.
[0009] The present invention uses Staphylococcus aureus as a host to isolate a bacteriophage with high titer, wide lysis spectrum, good temperature and pH stability, and strong lysis ability, and studies its biological characteristics and performs classification identification and genome sequencing.
[0010] As described above, the use of Staphylococcus aureus phage SapLY01 in inhibiting Staphylococcus aureus.
[0011] The Staphylococcus aureus phage SapLY01 was prepared into a phage suspension as described above and then used to inhibit Staphylococcus aureus at 28°C.
[0012] Preferably, the phage suspension is prepared by mixing the Staphylococcus aureus phage SapLY01 and the host bacterial culture at a volume ratio of 1:1 for 15 minutes, adding 10 mL of LB liquid culture medium, culturing at 37°C for 6 hours, centrifuging at 4°C and 12000 rpm for 20 minutes, taking the supernatant, filtering with a 0.22 μm filter membrane, and the filtrate is the phage lysate. DNase I and RNase A was added to a final concentration of 1 μg / mL, incubated at 37°C for 30 min, NaCl was added to a final concentration of 1 M and ice-bathed for 1 h (i.e., sodium chloride was added to make the final concentration of sodium chloride in the mixed solution 1 M), centrifuged at 4°C and 12000 rpm for 10 min, the supernatant was added with PEG8000 at a final concentration of 10%, incubated at 4°C overnight, then centrifuged at 4°C and 12000 rpm for 10 min, the supernatant was discarded, inverted for 5 min, SM buffer was added to the remaining solid matter for resuspending, an equal volume of chloroform was added and gently shaken for 30 s, centrifuged at 4°C and 5000 rpm for 15 min, and the hydrophilic phase containing the phage particles was recovered to obtain a phage suspension.
[0013] Preferably, the host bacteria culture is host bacteria YZ4 streaked on 1.2% LB solid medium, cultured overnight, single clones were picked and inoculated into 5 mL LB (Luria broth) liquid medium, and cultured at 37° C. with shaking for 8 hours as host bacteria culture.
[0014] Preferably, the SM buffer is prepared by weighing 6.055 g Tris-HCl (pH 7.5) to 100 mL, adding 5.800 g NaCl and 2.000 g MgSO4, and then adding ddH2O to 1 L; the LB (Luria broth) liquid culture medium is prepared by adding 10 g peptone, 5 g yeast powder, and 10 g NaCl, adding ddH2O to 1 L, adjusting the pH to 7.0, and sterilizing by high pressure at 121°C for 20 min.
[0015] A phage composition comprises the Staphylococcus aureus phage SapLY01 or the phage suspension as described above.
[0016] A water disinfectant, the active ingredients of which include the Staphylococcus aureus phage SapLY01, the phage suspension or the phage composition as described above; and other active ingredients used for inhibiting or eliminating viruses and bacteria in the environment.
[0017] The disinfectant can be used to disinfect the breeding environment, feeding equipment and feed from Staphylococcus aureus by spraying or soaking.
[0018] A biological antibacterial agent for disinfecting aquatic products, comprising the Staphylococcus aureus phage SapLY01, the phage suspension or the phage composition as described above; the method for using the biological antibacterial agent is: immersing or spraying the surface of the aquatic product for disinfection to inhibit the proliferation of Staphylococcus aureus during product processing or preservation.
[0019] Compared with the prior art, the present invention has the following beneficial effects:
[0020] The Staphylococcus aureus phage SapLY01 of the present invention has a short incubation period, a wide lysis spectrum, a strong lysis ability, can quickly kill host bacteria, has small toxic and side effects, is highly safe, has a relatively wide temperature and acid-base tolerance range, has good hydrophilicity, is easy to prepare into a spray and an injection, can effectively kill clinically isolated Staphylococcus aureus, can effectively inhibit Staphylococcus aureus from polluting the environment, and has a good therapeutic effect on animals infected with Staphylococcus aureus.
[0021] Storage Information
[0022] Staphylococcus aureus phage SapLY01 was deposited in the China Center for Type Culture Collection (CCTCC) on January 4, 2024, with the deposit number CCTCC NO: M2024014. BRIEF DESCRIPTION OF THE DRAWINGS
[0023] Figure 1 This is a plaque picture of the Staphylococcus aureus phage SapLY01 of the present invention.
[0024] Figure 2 This is a scanning electron microscope image of the Staphylococcus aureus phage SapLY01 of the present invention.
[0025] Figure 3 This is the optimal infection multiplicity diagram of the Staphylococcus aureus phage SapLY01 of the present invention.
[0026] Figure 4 It is a one-step growth curve diagram of the Staphylococcus aureus phage SapLY01 of the present invention.
[0027] Figure 5 It is a schematic diagram of the effect of temperature on the activity of the Staphylococcus aureus phage SapLY01 of the present invention.
[0028] Figure 6 It is a schematic diagram of the effect of pH on the activity of the Staphylococcus aureus phage SapLY01 of the present invention.
[0029] Figure 7 This is a schematic diagram of the sterilization of Staphylococcus aureus phage SapLY01 in milk; wherein A is at 4°C, and B is at 28°C.
[0030] Figure 8 This is a schematic diagram of the sterilization of Staphylococcus aureus phage SapLY01 in fresh pork; wherein A is at 4°C, and B is at 28°C. DETAILED DESCRIPTION
[0031] The specific implementation is described in detail below in conjunction with the accompanying drawings, but it should be understood that the protection scope of the present invention is not limited by the specific implementation. The raw materials and reagents used in the examples are all commercially available unless otherwise specified.
[0032] The host bacteria used in the embodiment is Staphylococcus aureus YZ4, which is a clinical strain of Staphylococcus aureus, isolated from cow feces in a dairy farm in Nanjing, Jiangsu Province, and is co-preserved with the Staphylococcus aureus phage SapLY01 of the present invention in the China Center for Type Culture Collection, with a preservation address of Wuhan University, Bayi Road, Wuchang District, Wuhan City, Hubei Province, and a preservation number of CCTCC NO: M 2024014.
[0033] The whole genome sequencing of the Staphylococcus aureus phage SapLY01 of the present invention has been completed by Sangon Biotechnology (Shanghai) Co., Ltd., and the sequence has been uploaded to the GenBank database with the accession number OR836606.1, which can be searched and downloaded on the official website of the National Center for Biotechnology Information (NCBI).
[0034] LB (Luria broth) liquid medium (1 L): peptone 10 g, yeast powder 5 g, NaCl 10 g, add ddH2O to 1 L, adjust pH to 7.0, and sterilize at 121°C for 20 min.
[0035] 0.6% LB semisolid medium (1 L): peptone 10 g, yeast powder 5 g, NaCl 10 g, agar powder 6 g, add ddH2O to 1 L, adjust pH to 7.0, and sterilize at 121°C for 20 min.
[0036] 1.2% LB solid medium (1L): 10g peptone, 5g yeast powder, 10g NaCl, 12g agar powder, add ddH2O to 1L, adjust pH to 7.0, sterilize at 121℃, autoclave for 20min, cool to 50℃, pour into a plate, cool and solidify, then invert for later use.
[0037] SM buffer (1 L): weigh 6.055 g Tris-HCl (pH 7.5) to make up to 100 mL, add 5.800 g NaCl and 2.000 g MgSO4, and then add ddH2O to make up to 1 L.
[0038] 1 mol / L sterile CaCl2 solution (1L): Weigh 111g of CaCl2 solid using a balance, pour into a beaker and add water to dissolve, pour the solution into a 1L volumetric flask and rinse the beaker with distilled water three times, pour the rinse solution into the volumetric flask, make up to volume, and sterilize under high pressure for later use.
[0039] DNase I, RNase A, PEG8000, and phosphotungstic acid (PTA, 2% w / v) were commercially available.
[0040] Example 1
[0041] Isolation of Staphylococcus aureus phage SapLY01
[0042] The phage sample was collected from the sewage in the septic tank of a pig farm in Nanning, Guangxi. The sample was centrifuged at 4°C and 12000rpm for 10 minutes, and the supernatant was centrifuged repeatedly for 3 times. Finally, the supernatant was filtered with 0.45μm and 0.22μm filter membranes respectively; 5mL of the filtrate was taken, and 0.1mL was added with Staphylococcus aureus YZ4 as the host bacteria, and 5mL of 2×LB liquid culture medium (2×LB liquid culture medium is double the concentration of LB liquid culture medium) was added, and it was placed at 37°C for 14-16h. The next day, the culture obtained after the above culture for 14-16h was centrifuged at 4°C and 12000rpm for 10min, and the supernatant was filtered and sterilized with a 0.22μm filter membrane to obtain the original solution containing the phage, that is, the phage suspension.
[0043] The host bacteria YZ4 was streaked and inoculated on 1.2% LB solid medium. After culturing overnight, a single clone was picked and inoculated into 5 mL LB (Luria broth) liquid medium. After shaking culture at 37° C. for 8 h, it was used as the host bacteria culture for later use.
[0044] Divide the 1.2% LB solid culture medium into two areas, take 0.1 mL of the above-mentioned reserved host bacteria culture and 3 mL of 0.6% LB semi-solid, mix them evenly and spread them on the 1.2% LB solid culture medium. After it is dried, take 10 μL of the above-mentioned phage suspension and drop it on one of the areas. After it is naturally dried, place it in a 37°C incubator for culture, and observe whether there are plaques formed in the phage drop area. If plaques are formed, it proves the presence of phages.
[0045] Take another 0.1 mL portion of the phage suspension and dilute it 10 times. -2 , 10 -4 , 10 -6 0.1 mL of the diluent was added to 0.1 mL of the host bacteria, and the mixture was allowed to stand for 15 min. 3.5 mL of 0.6% LB semi-solid medium at about 45° C. was added, and the mixture was evenly spread on the pre-prepared 1.2% LB solid medium. After culturing at 37° C. for 8 h, the growth of the plaques was observed. A single transparent plaque without a halo, uniform in size, and neatly edged was selected and placed in an EP tube containing 0.1 mL of the host bacteria culture and LB liquid medium, and co-cultured at 37° C. overnight. The co-culture was centrifuged and filtered on the next day, and the filtrate was diluted 10 times with SM buffer, and purified with 0.1 mL of the host bacteria by the double-layer plate method. This was repeated about 10 times to obtain a phage with uniform plaque size. The phage was named SapLY01 and stored at 4° C. for later use.
[0046] The above-mentioned spare phages were tested by double-layer plate method, and the results were as follows Figure 1 As shown, the phage can form clear plaques in agar culture medium, with no halo around, clear and regular edges, and a diameter of about 0.1 mm, which is a typical lytic phage.
[0047] Example 2
[0048] Amplification and Purification of Staphylococcus aureus Phage SapLY01
[0049] Take 0.1 mL of the bacteriophage SapLY01 stored at 4°C in Example 1 and 0.1 mL of the host bacteria culture stored in Example 1 in a test tube for 15 min, add 10 mL of LB liquid culture medium, culture at 37°C for 6 h, centrifuge at 4°C and 12000 rpm for 20 min, take the supernatant, filter with a 0.22 μm filter membrane, and the filtrate is the phage lysate.
[0050] PEG purification: DNase I and RNase A were added to the phage lysate to a final concentration of 1 μg / mL, incubated at 37°C for 30 min, added with NaCl to a final concentration of 1 M and placed on ice for 1 h (i.e., sodium chloride was added to make the final concentration of sodium chloride in the mixed solution 1 M), centrifuged at 4°C and 12000 rpm for 10 min, the supernatant was added with PEG8000 to a final concentration of 10%, incubated at 4°C overnight, then centrifuged at 4°C and 12000 rpm for 10 min, the supernatant was discarded, inverted for 5 min, excess water was removed as much as possible, and then SM buffer was added to the remaining solid matter to resuspend, an equal volume of chloroform was added and gently shaken for 30 s, centrifuged at 4°C and 5000 rpm for 15 min to separate the organic phase and the hydrophilic phase, and the hydrophilic phase containing the phage particles was recovered to obtain a purified phage suspension.
[0051] The double-layer plate method was used to detect the phage titer: the purified phage suspension was diluted 10 times in a gradient, 0.1 mL of the phage dilution in each gradient was taken and mixed with 0.1 mL of the host bacterial solution, and then spread on a double-layer agar plate. The plate was cultured at 37°C for about 6-10 h, and the plaques were counted on each agar plate. The plate with about 30-300 plaques was selected. The initial phage concentration calculated according to the dilution multiple was the phage titer. The phage titer (PFU / mL) = dilution multiple × number of plaques × 10, and the phage titer was 7 × 10 8 PFU / mL.
[0052] Example 3
[0053] Observation of Staphylococcus aureus phage SapLY01 by transmission electron microscopy
[0054] The purified phage SapLY01 suspension of Example 2 was observed under an electron microscope. The purified phage suspension of Example 2 was dropped on a copper sheet and allowed to precipitate naturally for 5 to 10 minutes. The excess liquid was removed with filter paper, and a drop of 2% phosphotungstic acid (PTA, 2% w / v) was added for staining. After drying at room temperature, the suspension was observed under a transmission electron microscope. The results are shown in FIG. Figure 2As shown in the figure, the purified phage SapLY01 has a regular icosahedral structure with a head diameter of 100nm and a short tail of about 73nm, belonging to the family of tailed phages. It is named Staphylococcus aureus phage SapLY01 (Staphylococcus aureus phageSapLY01), and was deposited in the China Center for Type Culture Collection on January 4, 2024, with the deposit number CCTCC NO: M2024014.
[0055] Example 4
[0056] Determination of the optimal infection multiplicity of Staphylococcus aureus phage SapLY01 (the infection multiplicity is the ratio of the number of phages to the number of host bacteria at the initial stage of infection)
[0057] Take the host bacterial culture prepared in Example 1 and adjust the concentration to 1×10 8 CFU / mL, the bacteriophage SapLY01 stored at 4°C in Example 1 and the host bacteria culture stored in Example 1 were added at a ratio of 100, 10, 1, 0.1, 0.01, and 0.001, respectively, and LB liquid culture medium was added to make the total volume of the culture system the same, and static culture was carried out at 37°C for 5h, centrifuged at 10000rpm for 10min, and the supernatant was collected and diluted to an appropriate concentration. The titer was determined by the double-layer method. The results are as follows. Figure 3 As shown, the optimal infection multiplicity of Staphylococcus aureus phage SapLY01 is 0.1.
[0058] Example 5
[0059] Determination of one-step growth curve of Staphylococcus aureus phage SapLY01
[0060] The host bacterial culture prepared in Example 1 was adjusted to 1×10 8CFU / mL was mixed with an excess of the bacteriophage SapLY01 stored at 4°C in Example 1 (MOI>10, ensuring that all bacteria and phages were adsorbed), incubated at 37°C for 15min, centrifuged at 12000rpm for 1min, the supernatant (unadsorbed phage) was discarded, the precipitate (mutually adsorbed bacteria and phage particles) was washed once with LB liquid culture medium, the precipitate was resuspended with 10mL of preheated LB liquid culture medium, and quickly placed in a 37°C shaker for shaking culture. Starting from 0min, 120μl of the culture was taken every 10min, centrifuged at 4°C and 10000rpm for 2min to remove the bacteria, the supernatant was taken and diluted to an appropriate concentration (an appropriate concentration is a concentration that forms 30-300 plaques on the plate), the phage titer was determined by the double-layer method, and the measurement was performed for 120min. A total of 12 samples were taken, with the sampling time as the horizontal axis and the logarithm of the phage titer as the vertical axis. A one-step growth curve was drawn to obtain the incubation period, outbreak period, and outbreak volume of the phage. The one-step growth curve results are as follows Figure 4 As shown, the incubation period of host infection is about 30 minutes, the outbreak period is 40 minutes, and the outbreak volume is 251 PFU / cell.
[0061] Example 6
[0062] Temperature and pH tolerance experiment of Staphylococcus aureus bacteriophage SapLY01
[0063] Take 10 sterile EP tubes, add 0.5 mL of the bacteriophage SapLY01 stored at 4°C in Example 1 to each tube, and act at 30°C, 40°C, 50°C, 60°C, 70°C, and 80°C for 30 min and 60 min, respectively. After the action time, immediately place in a water bath to cool, and then measure the titer of the bacteriophage; the test results are as follows: Figure 5 As shown: the phage can withstand high temperatures of 50°C, and the titer is basically stable within 60 minutes. When the temperature is above 60°C, the phage titer decreases significantly over time. In a 60°C environment, the titer is basically stable within 30 minutes, and begins to decrease to inactivation after 60 minutes. The phage is rapidly inactivated in 70°C and 80°C environments.
[0064] 0.1 mL of the phage stored at 4°C in Example 1 was placed in SM buffer (0.9 mL) at pH 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, and 12, respectively, and allowed to react at 37°C for 1-2 h. The titer of the phage after the reaction was then determined by the double-layer method. The test results were as follows: Figure 6 As shown: the titer of Staphylococcus aureus phage SapLY01 changes little in an environment with a pH value of 6-9, and the activity remains basically unchanged; when the environmental pH is > 9 or pH < 6, the titer of the phage decreases sharply with the increase of acidity and alkalinity; when pH > 11 or pH < 4, the phage titer is 0 and is completely inactivated. Therefore, it can be seen that the optimal pH of the phage is 6-10.
[0065] Example 7
[0066] Analysis of host spectrum of Staphylococcus aureus phage SapLY01
[0067] The titer of bacteriophage SapLY01 stored at 4°C in Example 1 was adjusted to 10 8 PFU / mL was used for standby use. The host spectrum of phages was analyzed using 20 strains of Staphylococcus aureus isolated from various places in Jiangsu. The specific operation was as follows: 0.1mL of the overnight culture of 20 strains of Staphylococcus aureus was taken, 3mL of 0.6% LB semi-solid medium at about 45°C was added, and evenly spread on the pre-prepared 1.2% LB solid medium. Then each plate was divided into two areas, and 10μL of the titer was adjusted to 10 in one area. 8 PFU / mL of the above-mentioned reserved phage was dripped on the surface, and physiological saline was dripped on another area as a control. After the droplet dried, it was inverted and cultured at 37°C for 12 hours. The results were observed. If plaques were produced, it was recorded as "+", otherwise it was recorded as "-". The results are shown in Table 1: The lysis rate of Staphylococcus aureus phage SapLY01 was about 47% (16 / 34 strains of Staphylococcus aureus).
[0068] Table 1. Host spectrum of Staphylococcus aureus phage SapLY01
[0069]
[0070]
[0071] Note: Italics + bold are host bacteria.
[0072] Example 8
[0073] Bactericidal effect of Staphylococcus aureus phage SapLY01 in dairy products Five bovine Staphylococcus aureus strains (JSSA JC4, JSSA RZ1, JSSA RZ9, JSSA XY1, and JSSA YZ4) were randomly selected from the host spectrum and cultured to the logarithmic growth phase. The concentration of each bacterial strain was adjusted to 1×10 8 CFU / mL, and mixed according to the volume ratio of 1:1:1:1:1 and recorded as Staphylococcus aureus mixed solution for later use.
[0074] Ultra-high temperature sterilized skim milk was purchased from the supermarket, 100uL of Staphylococcus aureus mixture was artificially inoculated into 10mL of milk, and then 10% of the final concentration of 10% was added. 7 and 10 8PFU / mL phage suspension (MOI of 0.1 and 1), and only 100uL of Staphylococcus aureus mixed bacterial solution was added to the control group. The experimental group and the control group were cultured at 25°C for 48h, and 1mL samples were taken out for treatment at 2, 4, 6, and 24h. Finally, the bacteria and phages in the sample were separated. In short, the sample was placed in a centrifuge and centrifuged at 6000g for 10min to separate the bacteria and phages, and the precipitated bacteria were resuspended in 1mL PBS, and the centrifugation and resuspension operations were repeated three times. The collected bacteria were spread on LB agar medium and the live bacteria were counted. The supernatant of the three separation operations was collected, and the supernatant was filtered through a 0.22um filter membrane and the phages were counted using the double-layer plate method. The experiment was repeated 3 times in each group and paralleled 3 times.
[0075] To verify the bacteriophage SapLY01's bacteriocidal effect in food matrices, milk samples at 28°C and 4°C were simulated. At both temperatures, bacteriophage SapLY01 could effectively control the number of bacterial mixtures in milk.
[0076] At 4°C, Figure 7 A. The number of bacteria in the control group without phage treatment increased to 7.1Log10CFU / mL, and the total number of bacteria in the phage treatment group at two MOIs was suppressed to about 4.5Log10CFU / mL in 24 hours. Since 4℃ is the storage temperature of bacteria and phages, that is, at this temperature, the number of phages and bacteria will not rise or fall significantly. When the experiment is carried out at this temperature, the bacterial growth is relatively slow, and the reproduction of phages depends on the host bacteria, so the antibacterial effect is not as good as at room temperature.
[0077] In milk at 28°C ( Figure 7 B), the number of bacteria in the control group continued to increase to about 8.5Log10CFU / mL as time went by. When treated with phages at MOI of 1 and 0.1, there was no significant inhibitory effect on the mixed solution of Staphylococcus aureus within 4 hours, but the number of all five strains of bacteria could be reduced after 6 hours. Under both MOIs, phage SapLY01 grew with bacteria before 6 hours, but after 6 hours, the phage began to inhibit the total amount of the five strains of bacteria in milk, and at 24 hours, the phage showed a good inhibitory effect on bacteria.
[0078] Example 9
[0079] Bactericidal effect of Staphylococcus aureus phage SapLY01 in fresh meat products
[0080] Use a sterile scalpel to cut fresh pork purchased from the market into 3×3 cm 2, weighing about 2g, was placed on a sterile tray and irradiated with ultraviolet light for 50 minutes. During this period, the sample was turned over to make it evenly irradiated to eliminate bacteria on the surface of the pork, and a sterile pork sample was obtained. 25μL of the above-prepared mixed bacterial solution of Staphylococcus aureus was evenly dripped on the sterile pork sample to obtain an artificially contaminated pork sample, which was placed in a clean bench to dry for 30 minutes.
[0081] Artificially contaminated pork samples were sterilized with bacteriophage SapLY01. In the phage group, 50 μL of phage suspension was evenly dripped on the surface of bacterially contaminated pork samples at MOI of 0.1 and 1, and then the samples were placed in a 4°C refrigerator and a 28°C incubator for 24 hours. In the control group, sterile SM buffer (50 mM Tris-HCL, 8 mM magnesium sulfate, 100 mM sodium chloride and 0.01% gelatin, pH 7.5) was used instead of phage. At 2, 4, 6, and 24 hours of incubation, a small piece of pork sample was cut with a sterile scalpel, homogenized with commercially available phosphate buffered saline (PBS), and then 1 mL of the homogenate was taken out and continuously diluted with PBS. 100 μL of the dilution was spread on TSA agar medium, and the number of bacteria was determined by bacterial plate counting. The experiment was repeated three times.
[0082] At 4°C, the results were Figure 8 A. Because the growth rate of bacteria is relatively slow, the replication of phages is indirectly inhibited. After 24 hours, the number of bacteria in the group without phage treatment only increased to 7.16Log10CFU / mL. In the first 4 hours, phages and bacteria grew together. At 6 hours, the total number of bacteria in the phage-treated group decreased compared with the group without phage treatment. The number of live bacteria in the phage-treated group with MOI=1 decreased by 1.7Log10CFU / mL, and the number of live bacteria in the phage-treated group with MOI=0.1 decreased by 1.1Log10CFU / mL. However, at 24 hours, the number of live bacteria in the phage-treated group with MOI=1 decreased by 2.91Log10CFU / mL, and the number of live bacteria in the phage-treated group with MOI=0.1 decreased by 1.6Log10CFU / mL. Under the environment of 28℃, the phage with MOI=1 has better control over the total number of bacteria.
[0083] At 28°C, the results are as follows Figure 8 B, The bacterial count continued to increase to 9.5Log10CFU / mL after 24 hours compared with the group without phage treatment. There was no significant difference between the two phage treatment groups with different MOIs. Both phage treatment groups showed obvious antibacterial effects after 6 hours. At 24 hours, the number of viable bacteria in the phage treatment group with MOI=1 decreased by 4.6Log10CFU / mL, and the number of viable bacteria in the phage treatment group with MOI=0.1 decreased by 3.7Log10CFU / mL compared with the group without phage treatment.
[0084] The application of bacteriophages is closely related to temperature, because the growth of bacteriophages mainly depends on the growth of the host to reproduce offspring. Bacteria usually grow faster at the optimal temperature, which indirectly promotes the replication of bacteriophages, and low temperature will indirectly cause the replication rate of bacteriophages to be significantly reduced or stopped. Therefore, the overall results show that the control effect of bacteriophage SapLY01 on the mixture of 5 wild bovine Staphylococcus aureus in milk in the room temperature group is better than that in the low temperature group.
[0085] The foregoing description of specific exemplary embodiments of the present invention is for the purpose of illustration and demonstration. These descriptions are not intended to limit the present invention to the precise form disclosed, and it is clear that many changes and variations can be made based on the above teachings. The purpose of selecting and describing the exemplary embodiments is to explain the specific principles of the present invention and its practical application, so that those skilled in the art can realize and utilize various different exemplary embodiments of the present invention and various different selections and changes. The scope of the present invention is intended to be limited by the claims and their equivalents.
Claims
1. A Staphylococcus aureus phage SapLY01, characterized in that: The Staphylococcus aureus phage SapLY01 is Staphylococcus aureus phage SapLY01, and its preservation number is CCTCC NO: M 2024014.
2. Use of the Staphylococcus aureus phage SapLY01 as claimed in claim 1 in inhibiting Staphylococcus aureus.
3. Use of the Staphylococcus aureus phage SapLY01 as claimed in claim 1 in inhibiting Staphylococcus aureus at 28°C after being prepared into a phage suspension.
4. The use of the Staphylococcus aureus phage SapLY01 according to claim 3 in inhibiting Staphylococcus aureus at 28° C. after being prepared into a phage suspension, characterized in that: The phage suspension is prepared by mixing the Staphylococcus aureus phage SapLY01 and the host bacteria culture in a volume ratio of 1:1, adding LB liquid culture medium, culturing at 37°C for 6h, centrifuging, taking the supernatant, filtering with a filter membrane, and the filtrate is the phage lysate. DNase I and RNase A are added to the phage lysate to a final concentration of 1 μg / mL, incubating at 37°C for 30min, adding NaCl ice bath, centrifuging, taking the supernatant and adding PEG8000, incubating at 4°C overnight, then centrifuging, discarding the supernatant, inverting, adding SM buffer to the remaining solid matter for re-suspending, adding an equal volume of chloroform for shaking, centrifuging, and recovering the hydrophilic phase containing phage particles to obtain a phage suspension.
5. The use of the Staphylococcus aureus phage SapLY01 according to claim 4 in inhibiting Staphylococcus aureus at 28° C. after being prepared into a phage suspension, characterized in that: The host bacteria culture is host bacteria YZ4 streaked and inoculated on 1.2% LB solid medium. After culturing overnight, a single clone is picked and inoculated into 5 mL LB liquid medium. After shaking culture at 37° C. for 8 hours, it is used as the host bacteria culture.
6. The use of the Staphylococcus aureus phage SapLY01 according to claim 4 in inhibiting Staphylococcus aureus at 28° C. after being prepared into a phage suspension, characterized in that: The SM buffer solution is prepared by weighing 6.055 g Tris-HCl to 100 mL, adding 5.800 g NaCl and 2.000 g MgSO4, and then adding ddH2O to 1 L. The LB liquid culture medium is prepared by adding 10 g peptone, 5 g yeast powder, and 10 g NaCl, adding ddH2O to 1 L, adjusting the pH to 7.0, and sterilizing by high pressure at 121°C for 20 min.
7. A bacteriophage composition, characterized in that: It comprises the Staphylococcus aureus phage SapLY01 according to claim 1 or the phage suspension according to claim 3.
8. A water disinfectant, characterized in that: The active ingredients include the Staphylococcus aureus phage SapLY01 as described in claim 1, the phage suspension as described in claim 3 or the phage composition as described in claim 7; and other active ingredients for inhibiting or eliminating viruses and bacteria in the environment are also included.
9. The water disinfectant according to claim 8, characterized in that: The disinfectant can be used to disinfect the breeding environment, breeding equipment and feed from Staphylococcus aureus by spraying or soaking.
10. A biological antibacterial agent for disinfection of aquatic products, characterized in that: The Staphylococcus aureus phage SapLY01 according to claim 1, the phage suspension according to claim 3 or the phage composition according to claim 7.
Citation Information
Patent Citations
Staphylococcus aureus phage and bacteriostatic application thereof
CN113621584A
Staphylococcus aureus phage SapYZUalpha and application thereof
CN114807058A
Wide-splitting-spectrum staphylococcus aureus bacteriophage SapYZUbeta and application thereof
CN116064413A
Separation and application of novel MRSA virulent bacteriophage vBSA2868B2 with strong lysis property
CN116731980A
Bacteriophage compositions and methods for treatment of bacterial infections
US20240180980A1
